Vimta Labs Ltd (VIMTALABS) is currently trading at 508.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Vimta Labs is an Indian contract research and testing organization serving pharmaceutical, biopharmaceutical, food, electronics, healthcare, medical-device, agrochemical and industrial customers through analytical, preclinical, clinical, diagnostics, environmental and EMI/EMC testing services. Q2 FY27 revenue increased 9.9% year-on-year to INR114.9 crore, while EBITDA grew 10.5% to INR40.8 crore and the margin reached 35.5%. Profit after tax rose more modestly by 3.5% to INR20.6 crore, indicating that operating improvement was partly offset below EBITDA. The company’s largest growth opportunity is biologics CRADS, where initial revenue has begun after approximately INR20–25 crore of investment. Management expects meaningful scale to take several years, but project economics can be substantially larger than conventional small-molecule assignments and provide cross-selling potential with existing customers. Growth has temporarily lagged the large capex program because pharmaceutical R&D pipelines slowed, food export-import samples were disrupted, and clinical recovery requires 12–18-month lead times. However, inquiries and proposals are rising, preclinical services are growing strongly, and H2 is expected to benefit from improving conversions. Vimta remains net debt-free on a management basis, with INR70.1 crore of cash and cash equivalents, despite taking approximately INR15 crore of long-term borrowing. Management stated that borrowing was economically attractive relative to using internal cash and preserved liquidity for potentially attractive opportunities.

Over the past 52 weeks, Vimta Labs Ltd has traded between a low of ₹377.30 and a high of ₹675.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Vimta Labs Ltd has a market capitalization of approximately 2,270.75. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Vimta Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 37.35 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,270.75 Cr, Vimta Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Vimta Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Vimta Labs Ltd is 37.35. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Vimta Labs has reaffirmed a FY28 revenue target of Rs 700 crore. Management also confirmed the 20%-25% medium-term revenue CAGR discussed during the Q2 FY27 call, but did not give quarterly revenue guidance.

VIMTA began in 1984 with 500 square feet, six people and testing focused on minerals, metals and rice bran oil. Its 2024 journey snapshot reports about 600,000 square feet and more than 1,300 people, while the company overview lists 10 labs and offices across India.

Vimta’s PAT margin fell to 17.9% in Q2 FY27 from 19.1% in Q2 FY26. Material and testing costs rose to Rs 26.2 crore from Rs 20.1 crore, while depreciation increased to Rs 12.9 crore from Rs 10.2 crore. These increases outpaced the 9.9% rise in total income.

Vimta Labs reported revenue from operations of Rs 111.983 crore for the quarter ended September 30, 2026. That was 9.95% higher than Rs 101.848 crore in the quarter ended September 30, 2025. Including other income, total income was Rs 114.887 crore.